内源性腺在除后节律失常症和血液动力学抑郁症中的作用
1Department of Medicine, University of Virginia Medical Center, Charlottesville.
Circulation
|July 1, 1989
概括
BW-A1433U是一种腺素对抗剂,有效地预防和逆转除后的节律失常和血液动力学抑郁. 这表明内源性腺在除后心血管崩中起着关键作用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 脱发动脉后的肌节律失常和血液动力学抑郁是显著的临床问题.
- 腺因被认为是除后心血管崩的调解者.
研究的目的:
- 在猪模型中研究氨酸对抗剂BW-A1433U对脱发动脉后勃拉地亚律和血液动力学抑郁的作用.
- 为了确定阻断腺的效果是否可以减轻除后的不良心血管事件.
主要方法:
- 在用氧化麻醉的猪中使用了两种方案.
- 协议1:BW-A1433U (5 mg/kg IV) 给药前后诱导了心室动发作 (15 秒).
- 协议2:BW-A1433U的作用与二皮里达摩尔 (核酸吸收阻断剂) 和甲索胺 (以抵消低血压) 进行了评估.
主要成果:
- BW-A1433U显著降低了心房阻塞后除的发生率 (6%与47%相比).
- 与单独的甲胺和二胺醇相比,BW-A1433U的使用增加了自发心跳和血压.
- 在二皮里达摩尔诱导的抑郁症期间,BW-A1433U迅速恢复了心率和血压.
结论:
- BW-A1433U有效地逆转并预防脱发动脉后肌肉节律不良和血液动力学抑郁症.
- 内源性腺可能是除后心血管崩的关键调解者.
- 氨酸对抗是一种潜在的治疗策略,用于管理除后的并发症.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...


